Title
A review on the effect of curcumin in cancer management
Authors
Aqeelah Benazir Hidayathullah, Lubna Fathima*, A. Banu Jothi, D. Prabu, M. Rajmohan, Dinesh Dhamodhar, R. Sindhu & R. Haripriya
Affiliation
Department of Public Health Dentistry, SRM Dental College, Ramapuram, Bharathi Salai, Chennai, India; *Corresponding author
Aqeelah Benazir Hidayathullah - E-mail: researchphdsrm@gmail.com
Lubna Fathima - E-mail: dr.lubnafathima@gmail.com
A. Banu Jothi - E-mail: banujothi7@gmail.com
D. Prabu - E-mail: drdp2017@gmail.com
M. Rajmohan - E-mail: rajmoham@srmist.edu.in
Dinesh Dhamodhar - E-mail: sindhudoc1908@gmail.com
R. Sindhu - E-mail: sindhudoc1908@gmail.com
R. Haripriya - E-mail: ravipriya9765@gmail.com
Article Type
Review
Date
Received July 1, 2026; Revised July 31, 2026; Accepted July 31, 2026, Published July 31, 2026
Abstract
Clinical evidence supporting curcumin’s anticancer efficacy remains inconsistent despite extensive experimental research. Therefore, it is of interest to evaluate the recent clinical trials investigating curcumin in cancer management. Available data shows the benefits in reducing oral mucositis, radiotherapy-induced toxicity, pain and inflammatory markers. However, poor bioavailability, heterogeneous formulations and variable dosing limit affect therapeutic outcomes. Thus, curcumin’s role as a supportive adjunct and highlighting priorities for future oncology research.
Keywords
Curcumin, clinical trials, anticancer, bioavailability
Citation
Hidayathullah et al. Bioinformation 22(7): 3817-3820 (2026)
Edited by
Ritik Kashwani
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
